SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

Insmed Incorporated logo
4 months ago

Director, Product Communications

Insmed Incorporated

New Jersey, USA (Hybrid)Full time$177K/yr – $242K/yr
Insmed Incorporated logo
4 months ago

Director, Marketing Pulmonary Vascular & Fibrotic Lung Diseases

Insmed Incorporated

New Jersey, USA (Remote)Full time$177K/yr – $242K/yr
Insmed Incorporated logo
5 months ago

Director, Marketing TPIP – Pulmonary Vascular & Fibrotic Lung Diseases

Insmed Incorporated

New Jersey, USA (Remote)Full time$177K/yr – $242K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Insmed Incorporated logo

Director, Product Communications

Insmed Incorporated

New Jersey, USA (Hybrid)

$177K/yr - $242K/yrIn-houseFull-timeDirector/executive12+ years exp.
4 months ago
Insmed Incorporated logo

Director, Marketing Pulmonary Vascular & Fibrotic Lung Diseases

Insmed Incorporated

New Jersey, USA (Remote)

$177K/yr - $242K/yrIn-houseFull-timeDirector/executive8+ years exp.
4 months ago
Insmed Incorporated logo

Director, Marketing TPIP – Pulmonary Vascular & Fibrotic Lung Diseases

Insmed Incorporated

New Jersey, USA (Remote)

$177K/yr - $242K/yrIn-houseFull-timeDirector/executive8+ years exp.
5 months ago
Insmed Incorporated logo
Insmed Incorporated

Director, Product Communications

New Jersey, USA (Hybrid)

$177K/yr – $242K/yrDirector/Executive12+ years expFull time

Posted 4 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive strategic communications for Insmed’s late-stage portfolio across clinical data, regulatory milestones, and market readiness.

  • Must-have: 12+ years in pharma brand or product communications with clinical data storytelling experience.
  • Standout: proven cross-functional leadership and collaboration across Regulatory, Medical Affairs, and Commercial teams.

Job Description

Responsibilities

  • Communications Leadership: Serve as the strategic communications partner for TPIP and priority pipeline programs, shaping narratives that elevate the science, clinical impact, and potential of Insmed’s late-stage portfolio.
  • Data and Regulatory Milestone Communications: Lead communications planning and execution for major clinical milestones – including clinical data readouts, regulatory filings and approvals – collaborating closely with key cross-functional partners, and ensuring clear, credible dissemination of results to media and other key stakeholders.
  • Disease State & Science Visibility: Drive initiatives that raise awareness of under-recognized respiratory diseases and the unmet needs patients face, helping establish the scientific and clinical context for pipeline innovations.
  • Launch Readiness & Market Preparation: Partner with global and U.S. commercial teams to build communications strategies that prepare the market ahead of potential launches, including disease education, scientific and patient storytelling, and stakeholder engagement.
  • Executive & Internal Communications: Partner with Corporate Communications and leadership to keep employees informed and inspired around pipeline progress, major data moments, and organizational milestones.
  • Cross-Functional Collaboration: Work seamlessly with Clinical Development, Commercial, Medical Affairs, Regulatory, Investor Relations, Corporate Communications and Corporate Brand/Digital Communications teams to ensure consistent and coordinated messaging and plans across all channels and stakeholders.

Requirements

  • You have a minimum of a Bachelor’s Degree and 12+ years of progressive experience brand or product communications.
  • Pharmaceutical industry experience (required); respiratory and rare disease experience (strongly preferred).
  • A combination of agency and in-house experience (strongly preferred).
  • Significant experience in clinical data communications, with a proven ability to translate complex science into compelling narratives and work across functions to secure alignment and approvals.
  • Demonstrated success leading communications for disease state awareness programming, regulatory milestones, and product launches.
  • Strong executive presence required, along with proven ability to fully integrate and participate in leadership teams.
  • Proficiency with AI-powered platforms and analytics tools, with demonstrated ability to integrate new AI technologies into existing

Preferred

  • Respiratory and rare disease experience (strongly preferred).
  • A combination of agency and in-house experience (strongly preferred).
  • Strong understanding of the healthcare media landscape and experience engaging with trade, scientific, and business press.

Benefits

  • Comprehensive medical, dental, and vision coverage and mental health support, annual wellbeing reimbursement, and access to our Employee Assistance Program (EAP)
  • Generous paid time off policies, fertility and family-forming benefits, caregiver support, and flexible work schedules with purposeful in-person collaboration
  • 401(k) plan with a competitive company match, annual equity awards, and participation in our Employee Stock Purchase Plan (ESPP), and company-paid life and disability insurance
  • Company Learning Institute providing access to LinkedIn Learning, skill building workshops, leadership programs, mentorship connections, and networking opportunities
  • Employee resource groups, service and recognition programs, and meaningful opportunities to connect, volunteer, and give back
Insmed Incorporated logo

Insmed Incorporated

4.1 Glassdoor

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. We are dedicated to making a meaningful impact in patients’ lives as well as the communities where we live and work. Our team is guided by our core values of collaboration, accountability, passion, respect, and integrity. Insmed is headquartered in Bridgewater, NJ, and has offices and research locations throughout the United States, Europe, and Japan. We are proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Join the Insmed team to accelerate your career and help make every moment and every patient count.Community guidelines: http://bit.ly/3DbEjVG

Founded in 1988
Bridgewater, New Jersey, USA
1.5K employees (69 in marketing)
www.insmed.com
77% recommend to a friend
97% CEO approval

Traffic Signals

Monthly Visitors
50.7K
Traffic Source Mix
Search
47.2%
Direct
41.7%
Referral
9.3%
Social
0.9%
Paid
0.8%

Headcount Trend

Current headcount: ~1.5K

Marketing Team

Marketing Team Size
66 (4% of company)
Median Career Experience
12 years
Median Tenure
3.9 years
Marketing Roles Posted (Last 30 Days)
2

People

HR / Recruitment

Morgan Langone
Morgan Langone
Senior Manager, Employer Brand & Recruitment Marketing
At the company for 1 year 7 months

Marketing Leadership

Deborah Kogan Eilender
Deborah Kogan Eilender
Head of Patient Marketing, ARIKAYCE
At the company for 5 years 5 months
Anna Lynn Storch
Anna Lynn Storch
Associate Director, Payer Marketing
At the company for 1 year 3 months
Katie Falbo
Katie Falbo
Senior Director, Global Strategy and Lifecycle Management
At the company for 4 years 1 month
Carly Lebel
Carly Lebel
Associate Director, Patient Marketing
At the company for 1 year 9 months

Funding

Total Funding
$4.6B
Last Raise
$750M
Post IPO Equity, 9 months ago

Funding History

  • Jun 2025
    Post IPO Equity • $750M
  • May 2024
    Post IPO Equity • $650M
  • May 2023
    Post IPO Equity • $500K

Recent News

Is EU Approval of First NCFB Therapy Reframing Insmed’s (INSM) Investment Outlook?
Nov 25, 2025 • Yahoo Finance
Insmed wins first EU approval for non-cystic fibrosis bronchiectasis treatment
Nov 20, 2025 • European Pharmaceutical Review
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
Nov 19, 2025 • Yahoo Finance
Insmed director Anderson sells $1.96 million in stock
Nov 18, 2025 • Investing.com
Insmed (INSM) Price Target Increased by 15.76% to 206.22
Nov 17, 2025 • Nasdaq
Here’s What Lifted Insmed Incorporated (INSM) in Q3
Nov 17, 2025 • Insider Monkey
A Fresh Look at Insmed (INSM) Valuation After Recent Share Price Surge
Nov 15, 2025 • Yahoo Finance
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good – Company Announcement
Nov 13, 2025 • Financial Times
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
Nov 13, 2025 • PR Newswire
Insmed (NASDAQ: INSM) holds fourth Global Day of Good with 1,200+ volunteers worldwide
Nov 13, 2025 • Stock Titan
Insmed Incorporated stock volume spike explained - 2025 Investor Takeaways & Weekly Chart Analysis and Guides
Nov 6, 2025 • newser.com
What machine learning models say about Insmed Incorporated - Market Risk Report & Pattern Based Trade Signal System
Nov 5, 2025 • newser.com
Approval of Brinsupri Lifted Insmed Incorporated (INSM) in Q3
Nov 3, 2025 • Yahoo Finance
Earnings Beat: Insmed Incorporated (NASDAQ:INSM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 2, 2025 • Yahoo Finance
Wells Fargo Maintains Insmed (INSM) Overweight Recommendation
Nov 1, 2025 • Nasdaq
Insmed (INSM) Hits All-Time High as Firm Posts Highly Optimistic Outlook
Oct 31, 2025 • Yahoo Finance
Insmed’s Promising Future: Are Gains Imminent?
Oct 30, 2025 • StocksToTrade
Earnings call transcript: Insmed Q3 2025 sees revenue beat, stock surges
Oct 30, 2025 • Investing.com
Insmed Inc (INSM) Q3 2025 Earnings Call Highlights: Strong Launch for Brin Suri and Robust ...
Oct 30, 2025 • Yahoo Finance
Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics
Oct 29, 2025 • Yahoo Finance
Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for
Oct 23, 2025 • Yahoo Finance
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
Oct 23, 2025 • PR Newswire
Insmed Inc stock reaches 52-week high at 167.0 USD
Oct 20, 2025 • Investing.com
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
Oct 17, 2025 • PR Newswire
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
Oct 16, 2025 • PR Newswire
Insmed Presents Six ASPEN Analyses, Late‑Breaking HRCT Results | INSM Stock News
Oct 16, 2025 • Stock Titan
Q3 2025 Results on Oct. 30 — Insmed Schedules Investor Call; Live Webcast & Replay
Oct 15, 2025 • Stock Titan
Does Insmed Incorporated (INSM) Have a Promising Pipeline?
Oct 15, 2025 • Yahoo Finance
Insmed Insiders Sold US$36m Of Shares Suggesting Hesitancy
Oct 11, 2025 • Yahoo Finance
Analyzing Insmed Stock After Positive FDA Filing News and Triple Digit Gains in 2025
Oct 3, 2025 • Sahm
Goldman Sachs Maintains Insmed (INSM) Buy Recommendation
Oct 3, 2025 • Nasdaq
Ohio Retirement Fund Invests in Insmed Incorporated (INSM)
Oct 2, 2025 • Yahoo Finance
Ohio Retirement Fund Invests in Insmed Incorporated (INSM)
Oct 2, 2025 • Insider Monkey
Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%
Sep 30, 2025 • MSN
Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality
Sep 30, 2025 • Seeking Alpha
Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%
Sep 30, 2025 • Insider Monkey
Insmed Incorporated (INSM) Rallies After FDA Approves Brinsupri, Shares Jump 9%
Sep 30, 2025 • Yahoo Finance
RBC Capital Remains Bullish on Insmed Incorporated (INSM)
Sep 26, 2025 • Yahoo Finance
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
Sep 22, 2025 • PR Newswire
Insmed to present multiple abstracts from ERS Congress 2025
Sep 22, 2025 • thefly.com
Insmed Incorporated to Present Multiple Abstracts At the European Respiratory Society Congress 2025
Sep 22, 2025 • MarketScreener
Caxton Associates LLP Makes New Investment in Insmed, Inc. $INSM
Sep 18, 2025 • MarketBeat
Insmed (INSM) Reported Impressive Results from the Phase 2 Trial of Its Inhalation Powder
Sep 12, 2025 • Yahoo Finance
Insmed at Morgan Stanley Conference: Strategic Growth and Innovation
Sep 9, 2025 • Investing.com
Transcript : Insmed Incorporated Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 04
Sep 9, 2025 • MarketScreener
DPP1 Inhibitor Market Set to Reach New Heights in the Coming Decade | DelveInsight
Sep 8, 2025 • DelveInsight Business Research LLP
115 New Hires Receive $9.6M+ in Stock Awards: Insmed's Major Talent Investment Under NASDAQ Rules
Sep 5, 2025 • Stock Titan
Insmed at Wells Fargo Conference: Strategic Growth and Future Plans
Sep 5, 2025 • Investing.com
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 5, 2025 • MarketScreener
Optum: 3 emerging specialty drugs payers should be watching
Sep 5, 2025 • Fierce Healthcare
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 5, 2025 • PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 5, 2025 • Morningstar.com
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri
Sep 4, 2025 • Pharmaceutical Technology
High-yielding BioPharma Credit puts more cash to work in 6.5% margin loan
Sep 3, 2025 • QuotedData
What Does Wall Street Think About Insmed Incorporated (INSM)?
Sep 2, 2025 • Insider Monkey
What Does Wall Street Think About Insmed Incorporated (INSM)?
Sep 2, 2025 • MSN
Insmed strength on United Therapeutics read through 'warranted,' says BofA
Sep 2, 2025 • thefly.com
United plots Tyvaso lung disease expansion with 'overwhelmingly positive' trial win
Sep 2, 2025 • FiercePharma
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results
Sep 2, 2025 • citybiz
Insmed revenue set to surge on Brinsupri launch
Aug 26, 2025 • S&P Global
How FDA Approval of BRINSUPRI for NCFB at Insmed (INSM) Has Changed Its Investment Story
Aug 22, 2025 • Yahoo Finance
Insmed To Present at September Investor Conferences
Aug 21, 2025 • Yahoo Finance
Insmed To Present at September Investor Conferences
Aug 21, 2025 • PR Newswire
Biotech Leader Insmed Announces Double-Header: Wells Fargo and Morgan Stanley Healthcare Conferences
Aug 21, 2025 • Stock Titan
Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Aug 21, 2025 • Benzinga.com
Insmed To Present at September Investor Conferences
Aug 21, 2025 • MarketScreener
Analyst recommendations: Intel, Roblox, Circle Internet, Insmed Inc, The Hershey Company…
Aug 20, 2025 • MarketScreener
Insmed Insider Sold Shares Worth $881,470, According to a Recent SEC Filing
Aug 20, 2025 • MarketScreener
Insmed: What The Approval Of Brinsupri Will Change?
Aug 17, 2025 • Seeking Alpha
The week in pharma: action, reaction and insight – week to August 15
Aug 17, 2025 • Pharma Letter
Insmed Stock Soars: What’s Next?
Aug 14, 2025 • StocksToTrade
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight
Aug 14, 2025 • DelveInsight Business Research LLP
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
Aug 13, 2025 • Stocktwits
VytlOne Announces New Partnership with Insmed
Aug 13, 2025 • Yahoo Finance
Insmed downgraded at Morgan Stanley despite FDA nod for lung therapy
Aug 13, 2025 • Seeking Alpha
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
Aug 13, 2025 • PR Newswire
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Aug 13, 2025 • Benzinga.com
STAT+: Pharmalittle: We’re reading about FDA OK for a lung disease drug, pharma sales in China, and more
Aug 13, 2025 • STAT
H.C. Wainwright doubles Insmed target to $240 on 'pipeline-in-a-pill' potential
Aug 13, 2025 • thefly.com
FDA approves Brinsupri for chronic inflammatory lung condition
Aug 13, 2025 • Pharma Letter
Insmed Wins Approval For First Bronchiectasis Drug and DPP1 Blocker
Aug 13, 2025 • BioSpace
FDA approves first drug for chronic lung condition bronchiectasis
Aug 13, 2025 • Medical Xpress - latest medical and health news stories
VytlOne Announces New Partnership with Insmed
Aug 13, 2025 • PR Newswire
Insmed gets first FDA approval for bronchiectasis
Aug 13, 2025 • pharmaphorum
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Aug 12, 2025 • Investor's Business Daily
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
Aug 12, 2025 • Yahoo Finance
Why Is Insmed Stock Trading Higher Today - Insmed (NASDAQ:INSM)
Aug 12, 2025 • Benzinga
Insmed Rises on Drug Approval for Debilitating Lung Disease
Aug 12, 2025 • Bloomberg.com
Insmed Targets $5bn-Plus Market With Brinsupri For Bronchiectasis
Aug 12, 2025 • insights.citeline.com
Insmed stock rises on FDA nod for lung disorder drug Brinsupri
Aug 12, 2025 • Seeking Alpha
FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis | PharmExec
Aug 12, 2025 • Pharmaceutical Executive
US FDA approves Insmed's drug as first treatment for a chronic lung disease
Aug 12, 2025 • Reuters
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Aug 12, 2025 • BioSpace
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Aug 7, 2025 • Insmed Incorporated Investor Relations
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Aug 7, 2025 • TradingView
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Aug 7, 2025 • Yahoo Finance
Insmed Incorporated 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:INSM) 2025-08-07
Aug 7, 2025 • Seeking Alpha
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
Aug 7, 2025 • PR Newswire
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
Aug 7, 2025 • Benzinga.com
Insmed reports Q2 EPS ($1.70), consensus ($1.31)
Aug 7, 2025 • thefly.com